Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study

Tanimoto, Takuya; Tada, S; Fujita, Suguru; Hirakawa, Tetsu; Matsumura, Mirai; Isoyama, Shoko; Ueno, Sayaka; Hamai, Kosuke; Tsuji, Naoki; Hirosawa, Hideyasu; Taniguchi, Tomohiro; Okamoto, Takeshi; Omoto, Takuji; Kusunoki, Shinji; Maeda, Hitoshi; Ishikawa, Nobuhisa

doi:10.1016/j.resinv.2022.02.004

Cited by 4 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the exclusion criteria, 6 articles were excluded after a full-text review. Finally, 6 studies [10,[14][15][16][17][18] were selected for inclusion in this meta-analysis. Overall, the meta-analysis included 920 patients, of whom 494 received baricitinib and 426 received standard care.…”

Section: Characteristics Of the Studiesmentioning

confidence: 99%

“…Five studies [10,14,[16][17][18] reported all-cause mortality within 60 days. Pooled analysis showed that 432 participants in the baricitinib group had a significantly lower mortality rate than 376 participants in the control group (17.1% vs 23.4%; OR = 0.61, P = .008, 95% CI 0.42-0.88; I 2 = 71%) (Fig.…”

Section: Assessment Of Outcomesmentioning

confidence: 99%

“…Six studies [10,[14][15][16][17][18] reported the length of hospital stay. Combined analysis showed that the length of hospital stay of 494 participants in the baricitinib group was similar to that of 426 participants in the control group, with no significant difference (OR = 1.54, P = .17, 95% CI -0.56-3.73; I 2 = 87%) (Fig.…”

Section: Assessment Of Outcomesmentioning

confidence: 99%

“…Six studies [10,[14][15][16][17][18] reported severe adverse events. Pooled analysis showed that the severe adverse event rates of 494 participants in the baricitinib group were similar to those of 426 participants in the control group, with non-significant differences (12.9% vs 13.6%; OR = 1.02, P = .93, 95% CI 0.66-1.58; I 2 = 69%) (Fig.…”

Section: Assessment Of Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis

Song,

Sun,

Feng

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19). Methods: Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to calculate the pooled estimates. The study protocol can be accessed at PROSPERO (CRD42023394173). Results: The baricitinib group had a significantly lower mortality rate and proportion of patients who received mechanical ventilation than the control group (OR = 0.61, 0.57; P = .008, 0.02; 95% CI 0.42–0.88; 0.35–0.92; I2 = 71% and 86%, respectively). The length of hospital stay and rates of severe adverse events were not significantly different between the 2 groups. Conclusion: Baricitinib reduces mortality and mechanical ventilation requirements in patients with severe COVID-19. Therefore, we developed a comprehensive understanding of the role of baricitinib in patients with severe COVID-19.

show abstract

Section: Characteristics Of the Studiesmentioning

confidence: 99%

Section: Assessment Of Outcomesmentioning

confidence: 99%

Section: Assessment Of Outcomesmentioning

confidence: 99%

Section: Assessment Of Outcomesmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis

Song,

Sun,

Feng

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…Tanimoto et al [39], in their propensity score-matched retrospective cohort study, recruited 229 patients in Hiroshima, Japan, to study the effect of baricitinib in comparison to standard of care on 30 and 60 day survival after admission. Other drugs such as favipiravir, corticosteroids, remdesivir, heparin and tocilizumab were also administered to both groups in similar proportions.…”

Section: Covid-19 Drug Development -Recent Advances New Perspectives ...mentioning

confidence: 99%

Baricitinib in the Treatment of COVID-19

Atal¹,

Sampath²,

Banerjee³

et al. 2022

COVID-19 Drug Development - Recent Advances, New Perspectives and Applications

View full text Add to dashboard Cite

Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to find all clinical studies on baricitinib in treatment of COVID-19. A total of 30 studies, including both clinical trials and observational studies were identified, and they have been described briefly. Collation of the results from these observational and interventional studies shows that baricitinib either alone or in combination with other drugs, when used as an add-on to standard therapy, was found to have favorable outcomes in hospitalized patients with moderate to severe COVID-19. Furthermore, ongoing clinical trials indicate that the drug is still under evaluation across the world for its safety and efficacy in COVID-19. The recent approval of baricitinib by the US FDA for treatment of hospitalized adults with COVID-19 accurately reflects the role of the drug in COVID-19. Baricitinib improves clinical outcomes in hospitalized COVID-19 patients, and additional evidence may establish the drug as a standard treatment in such patients.

show abstract

Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force

Tanaka

Chubachi

Namkoong

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Objectives To determine the effectiveness of baricitinib in patients with COVID-19, investigate whether baricitinib prevents the need for invasive mechanical ventilation, and identify patient subgroups that would benefit from baricitinib. Methods This observational matched cohort study was conducted by the Japan COVID-19 Task Force, a nationwide multicenter consortium. Patients with COVID-19 aged ≥18 years were identified from 70 hospitals in Japan. Among patients with confirmed COVID-19 from February 2020 to September 2021, those receiving baricitinib were propensity-score matched with controls. Results Among 3309 patients, 144 propensity score-matched pairs were identified. Thirteen (9.0%) patients in the baricitinib group and 27 (18.8%) in the control group required invasive mechanical ventilation during the disease course (odds ratio: 0.43). Although the baricitinib group had more severe disease, there were no significant differences in the intensive care unit admission rates (odds ratio: 1.16) and mortality rates (odds ratio: 0.74) between groups. In subgroup analyses, baricitinib was associated with a significant reduction in the need for invasive mechanical ventilation in patients requiring oxygen support (odds ratio: 0.28), with rapid shadow spread on chest radiography (odds ratio: 0.11), or treated with remdesivir (odds ratio: 0.27), systemic corticosteroids (odds ratio: 0.31), or anticoagulants (odds ratio: 0.17). Conclusions Baricitinib is effective at preventing the need for invasive mechanical ventilation in patients with COVID-19.

show abstract

Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study

Cited by 4 publications

References 8 publications

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis

Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis

Baricitinib in the Treatment of COVID-19

Propensity-Score Matched Analysis of the Effectiveness of Baricitinib in Patients With Coronavirus Disease 2019 (COVID-19) Using Nationwide Real-World Data: An Observational Matched Cohort Study From the Japan COVID-19 Task Force

Contact Info

Product

Resources

About